Kyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics"

Analysis Based on Head-to-Head Trial Shows Kyprolis With Lenalidomide and Dexamethasone Offers Substantial Value Over Previous Standard of Care in Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Calif., May 26, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Kyprolis Global Economic Model (K-GEM)1 has been published in the Journal of Medical Economics showing that in the United States (U.S.), Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) is cost-effective compared to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma. The K-GEM demonstrated an incremental cost-effectiveness ratio ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news